Literature DB >> 29091556

Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.

Mark Robson1, Carsten Goessl2, Susan Domchek3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29091556     DOI： 10.1056/NEJMc1711644

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  19 in total

Review 1.  Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial.

Authors:  Shams Reaz; Deimante Tamkus; Eran R Andrechek
Journal:  J Mol Med (Berl)       Date:  2018-01-08       Impact factor: 4.599

Review 2.  Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

Authors:  Narjust Duma; Kelly C Gast; Grace M Choong; Roberto A Leon-Ferre; Ciara C O'Sullivan
Journal:  Curr Oncol Rep       Date:  2018-06-08       Impact factor: 5.075

Review 3.  Esophageal carcinoma: Towards targeted therapies.

Authors:  Ali Fatehi Hassanabad; Rania Chehade; Daniel Breadner; Jacques Raphael
Journal:  Cell Oncol (Dordr)       Date:  2019-12-17       Impact factor: 6.730

Review 4.  Breast Cancer Genomics: Primary and Most Common Metastases.

Authors:  Caroline Bennett; Caleb Carroll; Cooper Wright; Barbara Awad; Jeong Mi Park; Meagan Farmer; Elizabeth Bryce Brown; Alexis Heatherly; Stefanie Woodard
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

5.  A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.

Authors:  Michael J Jelinek; Nathan R Foster; Alex J Zoroufy; Gary K Schwartz; Pamela N Munster; Tanguy Y Seiwert; Jonas A de Souza; Everett E Vokes
Journal:  Oral Oncol       Date:  2021-01-26       Impact factor: 5.337

6.  Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma.

Authors:  Lucía Trilla-Fuertes; Ismael Ghanem; Joan Maurel; Laura G-Pastrián; Marta Mendiola; Cristina Peña; Rocío López-Vacas; Guillermo Prado-Vázquez; Elena López-Camacho; Andrea Zapater-Moros; Victoria Heredia; Miriam Cuatrecasas; Pilar García-Alfonso; Jaume Capdevila; Carles Conill; Rocío García-Carbonero; Karen E Heath; Ricardo Ramos-Ruiz; Carlos Llorens; Ángel Campos-Barros; Angelo Gámez-Pozo; Jaime Feliu; Juan Ángel Fresno Vara
Journal:  Transl Oncol       Date:  2020-05-15       Impact factor: 4.243

7.  Implementing a comprehensive translational oncology platform: from molecular testing to actionability.

Authors:  Zahi I Mitri; Swapnil Parmar; Brett Johnson; Annette Kolodzie; Jamie M Keck; Max Morris; Alexander R Guimaraes; Brooke R Beckett; Uma Borate; Charles D Lopez; Kathleen A Kemmer; Joshi J Alumkal; Tomasz M Beer; Christopher L Corless; Gordon B Mills; Joe W Gray; Raymond C Bergan
Journal:  J Transl Med       Date:  2018-12-14       Impact factor: 5.531

Review 8.  Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.

Authors:  Anna Minchom; Caterina Aversa; Juanita Lopez
Journal:  Ther Adv Med Oncol       Date:  2018-07-13       Impact factor: 8.168

9.  Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment.

Authors:  Shipra Gandhi; Masanori Oshi; Vijayashree Murthy; Elizabeth A Repasky; Kazuaki Takabe
Journal:  Cancers (Basel)       Date:  2021-05-23       Impact factor: 6.575

10.  Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.

Authors:  Kristen E Mengwasser; Richard O Adeyemi; Yumei Leng; Mei Yuk Choi; Connor Clairmont; Alan D D'Andrea; Stephen J Elledge
Journal:  Mol Cell       Date:  2019-01-24       Impact factor: 19.328
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.